CD19 and acute lymphoblastic leukemia: Tisagenlecleucel (tisa-cel) is an anti-CD19 CAR T-cell therapy approved for the treatment of pediatric and young adult patients up to 25 years of age with R/R B-ALL while Brexucabtagene autoleucel (brexu-cel) is approved for the treatment of adult patients with R/R mantle cell lymphoma B-ALL.